| NCT ID | NCT07111884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prof. Dr. Hartmut Goldschmidt |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 999 participants |
| Start Date | 2022-12-08 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 999 participants in total. It began in 2022-12-08 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to collect long-term clinical follow-up data on patients with multiple myeloma who participated in a therapy study of the German-Speaking Myeloma Multicenter Group (GMMG). Target variables of interest are: Overall survival, progression-free survival and follow-up time. The relevant registry data will be provided and evaluated together with the therapy study data for scientific research projects. This allows seamless documentation of patient data from the end of the trial to long-term follow-up.
Eligibility Criteria
Inclusion Criteria: * Previous participation in a a therapy study of the GMMG study group Exclusion Criteria: * patients with organ amyloidosis at time of diagnosis
Contact & Investigator
Hartmut Goldschmidt, Prof.
PRINCIPAL INVESTIGATOR
University Hospital Heidelberg
Frequently Asked Questions
Who can join the NCT07111884 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07111884 currently recruiting?
Yes, NCT07111884 is actively recruiting participants. Contact the research team at eileen.kurre@med.uni-heidelberg.de for enrollment information.
Where is the NCT07111884 trial being conducted?
This trial is being conducted at Berlin, Germany, Berlin, Germany, Bielefeld, Germany, Bochum, Germany and 11 additional locations.
Who is sponsoring the NCT07111884 clinical trial?
NCT07111884 is sponsored by Prof. Dr. Hartmut Goldschmidt. The principal investigator is Hartmut Goldschmidt, Prof. at University Hospital Heidelberg. The trial plans to enroll 999 participants.